canakinumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
human origin 4952 914613-48-2

Description:

MoleculeDescription

Synonyms:

  • canakinumab
  • ilaris
  • ACZ885
a human anti-interleukin-1beta monoclonal antibody for treatment of cryopyrin-associated periodic syndrome
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
2.70 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
June 17, 2009 FDA NOVARTIS PHARMS
Oct. 23, 2009 EMA
Sept. 26, 2011 PMDA Novartis Pharma K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Inappropriate schedule of product administration 492.24 19.31 214 5666 71617 50527627
Pyrexia 229.40 19.31 249 5631 379954 50219290
Haemophagocytic lymphohistiocytosis 224.34 19.31 69 5811 8564 50590680
Incorrect dose administered 109.94 19.31 69 5811 48345 50550899
Clubbing 76.69 19.31 15 5865 272 50598972
Serum amyloid A protein increased 75.49 19.31 13 5867 111 50599133
Serum ferritin increased 72.46 19.31 26 5854 5176 50594068
Condition aggravated 63.42 19.31 119 5761 296939 50302305
COVID-19 41.50 19.31 38 5842 46624 50552620
Malaise 40.41 19.31 107 5773 335425 50263819
Illness 36.60 19.31 27 5853 24513 50574731
Cryopyrin associated periodic syndrome 35.93 19.31 5 5875 7 50599237
Pneumonia lipoid 35.67 19.31 7 5873 129 50599115
C-reactive protein increased 31.96 19.31 39 5841 66435 50532809
Juvenile idiopathic arthritis 31.31 19.31 12 5868 2867 50596377
Epstein-Barr virus infection 29.56 19.31 15 5865 6982 50592262
Lymphadenopathy 29.23 19.31 27 5853 33472 50565772
Product use in unapproved indication 29.20 19.31 50 5830 115769 50483475
Familial mediterranean fever 25.61 19.31 4 5876 17 50599227
Rash 25.27 19.31 109 5771 437362 50161882
Concomitant disease aggravated 24.77 19.31 14 5866 8077 50591167
Arthralgia 23.59 19.31 107 5773 438595 50160649
Gastroenteritis 22.74 19.31 20 5860 23261 50575983
SARS-CoV-2 test positive 22.68 19.31 11 5869 4648 50594596
Tonsillitis 22.10 19.31 11 5869 4912 50594332
Amyloidosis 21.93 19.31 7 5873 976 50598268
Asteatosis 21.62 19.31 4 5876 53 50599191
Urticaria 20.52 19.31 46 5834 129515 50469729
Viral infection 20.23 19.31 21 5859 29965 50569279
Cellulitis staphylococcal 20.05 19.31 6 5874 675 50598569
Syringe issue 20.01 19.31 8 5872 2136 50597108
Alveolar proteinosis 19.55 19.31 5 5875 315 50598929

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Apparent death 991.63 33.36 220 7453 3284 29563570
Diverticulitis 705.76 33.36 237 7436 17467 29549387
Joint swelling 505.11 33.36 249 7424 49381 29517473
Deep vein thrombosis 409.23 33.36 227 7446 57172 29509682
Pulmonary embolism 386.21 33.36 242 7431 76292 29490562
Pulmonary thrombosis 371.97 33.36 115 7558 6450 29560404
Red blood cell sedimentation rate increased 365.70 33.36 117 7556 7344 29559510
Renal failure 282.49 33.36 238 7435 118361 29448493
Pain 277.70 33.36 277 7396 171155 29395699
Terminal state 270.78 33.36 78 7595 3416 29563438
C-reactive protein abnormal 238.16 33.36 82 7591 6454 29560400
Inappropriate schedule of product administration 222.06 33.36 140 7533 44332 29522522
Thrombosis 184.08 33.36 123 7550 42922 29523932
C-reactive protein increased 176.21 33.36 121 7552 44142 29522712
Photosensitivity reaction 145.45 33.36 63 7610 9195 29557659
Drug ineffective 139.76 33.36 296 7377 362874 29203980
Haemophagocytic lymphohistiocytosis 131.56 33.36 61 7612 10443 29556411
Joint arthroplasty 124.49 33.36 30 7643 646 29566208
Intentional product use issue 118.92 33.36 94 7579 42404 29524450
Sepsis 110.74 33.36 159 7514 142523 29424331
Contraindicated product administered 107.56 33.36 64 7609 18202 29548652
Intestinal sepsis 104.40 33.36 24 7649 418 29566436
Herpes zoster 89.49 33.36 69 7604 29983 29536871
Arthropathy 83.44 33.36 58 7615 21496 29545358
Stomatitis 76.74 33.36 69 7604 37044 29529810
Interstitial lung disease 72.70 33.36 82 7591 57636 29509218
Feeling abnormal 69.67 33.36 78 7595 54367 29512487
Stent placement 66.61 33.36 29 7644 4277 29562577
Off label use 65.34 33.36 198 7475 300602 29266252
Drug intolerance 64.81 33.36 71 7602 48308 29518546
Urticaria 62.67 33.36 74 7599 54586 29512268
Knee arthroplasty 61.29 33.36 30 7643 5779 29561075
Serum amyloid A protein increased 60.83 33.36 11 7662 51 29566803
Pyrexia 49.45 33.36 175 7498 287447 29279407
Myocardial infarction 41.99 33.36 90 7583 110206 29456648
Juvenile idiopathic arthritis 41.25 33.36 15 7658 1379 29565475
Drug interaction 37.16 33.36 4 7669 197381 29369473
Drug hypersensitivity 35.98 33.36 64 7609 68342 29498512
Illness 35.68 33.36 22 7651 6652 29560202
Toxicity to various agents 34.04 33.36 3 7670 173658 29393196

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Apparent death 399.85 19.98 91 9966 2585 64486090
Pulmonary thrombosis 300.85 19.98 97 9960 10421 64478254
Inappropriate schedule of product administration 253.03 19.98 165 9892 92121 64396554
Terminal state 249.39 19.98 69 9988 4375 64484300
Haemophagocytic lymphohistiocytosis 248.39 19.98 96 9961 17513 64471162
Diverticulitis 216.13 19.98 110 9947 38508 64450167
Red blood cell sedimentation rate increased 210.56 19.98 101 9956 31134 64457541
Pyrexia 194.23 19.98 326 9731 558318 63930357
C-reactive protein increased 157.13 19.98 125 9932 94784 64393891
C-reactive protein abnormal 145.95 19.98 77 9980 28970 64459705
Thrombosis 136.45 19.98 102 9955 70540 64418135
Serum amyloid A protein increased 121.85 19.98 21 10036 129 64488546
Sepsis 103.88 19.98 152 9905 230189 64258486
Photosensitivity reaction 102.26 19.98 52 10005 18121 64470554
Deep vein thrombosis 93.92 19.98 98 9959 105084 64383591
Pulmonary embolism 91.00 19.98 113 9944 146243 64342432
Incorrect dose administered 87.78 19.98 74 9983 60691 64427984
Intestinal sepsis 80.79 19.98 19 10038 623 64488052
Renal failure 80.53 19.98 119 9938 181569 64307106
Joint swelling 77.29 19.98 128 9929 215254 64273421
Joint arthroplasty 71.54 19.98 22 10035 2018 64486657
Urticaria 65.97 19.98 97 9960 147220 64341455
Interstitial lung disease 58.35 19.98 74 9983 97658 64391017
Juvenile idiopathic arthritis 57.69 19.98 22 10035 3857 64484818
Herpes zoster 55.45 19.98 65 9992 79122 64409553
Stent placement 49.99 19.98 22 10035 5549 64483126
Pneumonia 48.04 19.98 193 9864 559383 63929292
Serum ferritin increased 46.95 19.98 24 10033 8444 64480231
Intentional product use issue 45.87 19.98 65 9992 95299 64393376
Pain 44.41 19.98 187 9870 553324 63935351
Tonsillitis 42.78 19.98 20 10037 5800 64482875
Clubbing 42.04 19.98 11 10046 562 64488113
Feeling abnormal 40.77 19.98 74 9983 133528 64355147
COVID-19 38.34 19.98 49 10008 65091 64423584
Familial mediterranean fever 37.07 19.98 7 10050 76 64488599
Stomatitis 36.39 19.98 63 9994 109542 64379133
Toxicity to various agents 35.16 19.98 7 10050 363506 64125169
Drug interaction 34.97 19.98 7 10050 362076 64126599
Concomitant disease aggravated 34.90 19.98 22 10035 11520 64477155
Illness 34.32 19.98 28 10029 21910 64466765
Myocardial infarction 33.01 19.98 77 9980 165744 64322931
Autoinflammatory disease 32.66 19.98 7 10050 149 64488526
Gastroenteritis 32.59 19.98 31 10026 29680 64458995
Asteatosis 30.78 19.98 6 10051 78 64488597
Condition aggravated 29.90 19.98 126 9931 372300 64116375
Cryopyrin associated periodic syndrome 27.04 19.98 5 10052 48 64488627
Dyspnoea 24.43 19.98 47 10010 718627 63770048
Drug ineffective 24.40 19.98 218 9839 840029 63648646
Otitis media 23.40 19.98 13 10044 5400 64483275
Product use in unapproved indication 22.93 19.98 70 9987 176548 64312127
Nausea 22.90 19.98 56 10001 785744 63702931
Fall 22.73 19.98 19 10038 416807 64071868
Lymphadenopathy 22.69 19.98 32 10025 46654 64442021
Contraindicated product administered 22.46 19.98 51 10006 107778 64380897
Inflammation 22.27 19.98 38 10019 65262 64423413
Upper respiratory tract infection 21.78 19.98 40 10017 72745 64415930
Hypotension 21.22 19.98 17 10040 380957 64107718
Viral infection 20.96 19.98 27 10030 36113 64452562
Lymphadenitis bacterial 20.74 19.98 4 10053 49 64488626
Arthropathy 20.68 19.98 53 10004 120914 64367761
Arthralgia 20.30 19.98 128 9929 442132 64046543
Muckle-Wells syndrome 20.00 19.98 3 10054 6 64488669

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AC08 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Familial Mediterranean fever indication 12579009 DOID:2987
Articular gout indication 48440001 DOID:13189
Deficiency of mevalonate kinase indication 124327008 DOID:0050452
Systemic onset juvenile chronic arthritis indication 201796004
TNF receptor-associated periodic fever syndrome (TRAPS) indication 403833009
Cryopyrin associated periodic syndrome indication 430079001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Interleukin-1 beta Cytokine ANTIBODY BINDING DRUG LABEL DRUG LABEL

External reference:

IDSource
D09315 KEGG_DRUG
4028805 VUID
N0000178497 NUI
4028805 VANDF
CHEMBL1201834 ChEMBL_ID
C541220 MESH_SUPPLEMENTAL_RECORD_UI
6773 IUPHAR_LIGAND_ID
8836 INN_ID
DB06168 DRUGBANK_ID
37CQ2C7X93 UNII
853491 RXNORM
165731 MMSL
26503 MMSL
d07451 MMSL
698091001 SNOMEDCT_US
703376008 SNOMEDCT_US
C2718773 UMLSCUI
013212 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ilaris HUMAN PRESCRIPTION DRUG LABEL 1 0078-0734 INJECTION, SOLUTION 150 mg SUBCUTANEOUS BLA 31 sections